Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covis Pharma BV

www.covispharma.com

Latest From GlaxoSmithKline PLC

GSK Trims Nutritional Drink Lines, Wants All Of Its Consumer JV Pie

With its July 26 earnings report, the UK firm made clear it's ready to become sole owner of its consumer health JV with Novartis, and that divesting UK brands Horlicks and MaxiNutrition are among its steps toward cutting manufacturing costs.

Consumer Business Strategies

Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

Dynavax has already received two complete response letters for its hepatitis B vaccine; more patients who received Heplisav died or experienced cardiovascular events compared with the competitor arm.

Advisory Committees Drug Safety

GSK Trims Nutritional Drink Lines, Wants All Of Its Consumer JV Pie

With its July 26 earnings report, the UK firm made clear it's ready to become sole owner of its consumer health JV with Novartis, and that divesting UK brands Horlicks and MaxiNutrition are among its steps toward cutting manufacturing costs.

Consumer Business Strategies

Commercial Capsules: Q2 Reporters, Mitsubishi Buy, Celltrion IPO, Renflexis Launch, Keytruda Fail, Ironwood and Vertex Trial Results

Q2 reporting is on a roll as GSK unveils a major shake-up under new CEO Walmsley; the prospect of a simplified route to approval may have helped Neuroderm secure Mitsubishi take-out; biosimilar developments include Celltrion Healthcare's IPO and Merck & Co's launch of Renflexis in the US; clinical trial updates were reported for Keytruda, Ironwood's GERD candidate and Vertex's next generation of cystic fibrosis candidates. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.

Commercial Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Immune Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Covis Pharma SARL
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Covis Pharma BV
  • Senior Management
  • Jack Davis, CEO
    Michael Porter, COO & CFO
  • Contact Info
  • Covis Pharma BV
    Phone: 748 04 04
    Bahnhofstrasse 11
    Zug Branch
    Zug, CH-6300
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register